Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette

  • 61 views
  • 22 Oct, 2022
  • 98 locations
A Phase Ib/II Study to Assess the Safety and Activity of DURvalumab (MEDI4736) in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE)

DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer

durvalumab
gilbert's syndrome
radical cystectomy
neutrophil count
invasive bladder cancer
  • 0 views
  • 12 Oct, 2022
  • 3 locations
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

) subjects with non-metastatic muscle invasive bladder cancer that qualify for ChRT with curative intent.

mitomycin
carcinoma
invasive bladder cancer
bladder tumor
bladder cancer
  • 6 views
  • 04 Oct, 2022
  • 3 locations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from …

  • 44 views
  • 16 Oct, 2022
  • 297 locations
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective and are seeking an alternative treatment option to radical …

intravesical bcg
neutrophil count
invasive bladder cancer
carcinoma in situ
bladder tumor
  • 19 views
  • 04 Oct, 2022
  • 7 locations
Phase II Single Center Open-Label Single-Arm Study of the Safety and Efficacy of Oncolytic Adenovirus H101 Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer Who Failed BCG Therapy

objective of this phase II clinical trial is to investigate the safety and efficacy of H101 combined with PD-1 inhibitor Camrelizumab in patients with non-muscle-invasive bladder cancer who failed BCG

invasive bladder cancer
bladder tumor
carcinoma
neutrophil count
  • 0 views
  • 20 Oct, 2022
  • 1 location
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients

mitomycin
cancer
transurethral resection
invasive bladder cancer
bladder tumor
  • 12 views
  • 23 Apr, 2022
  • 1 location
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality

atezolizumab
aptt
neutrophil count
invasive bladder cancer
bladder tumor
  • 41 views
  • 20 Feb, 2022
  • 10 locations
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

bladder cancer (NMIBC).

neutrophil count
invasive bladder cancer
bladder tumor
carcinoma
intravesical administration
  • 1 views
  • 19 Apr, 2022
  • 1 location
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Gu(SqrRoot)(Copyright)Rin (BCG)

Background Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the

luteinizing hormone
durvalumab
intravesical bcg
bcg vaccine
neutrophil count
  • 257 views
  • 23 Oct, 2022
  • 1 location